~~<i id='DC04D3F8E1'><strike id='DC04D3F8E1'><tt id='DC04D3F8E1'><pre id='DC04D3F8E1'></pre></tt></strike></i>~~

Home» explore» comprehensive

comprehensive

author：knowledge 2025-09-27 13:57:06 Page View：9325

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional drug candidates for its pipeline of cardiometabolic medicines.

Cardior focuses on targeting RNA to address the root causes of heart disease. Its lead candidate, known CDR132L, is in Phase 2 development as a treatment for health failure.

The companies did not disclose how much Novo was paying upfront for Cardior and how much would be based on future milestones being achieved. The deal is expected to close in the second quarter.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA panel signals lack of confidence in Amgen cancer drug data
Next article： What does generative AI mean for health care? We asked experts

focus

Cancer drug shortages should be causing more outrage

DrugshortagesareagrowingproblemintheU.S.,andashortageoflivesavingcancerdrugsinparticularhasreachedcr

How to improve immunocompromised access to mAb treatments

Monoclonalantibodiesfightagroupofcoronaviruscellsina3Drendering.AdobeAstheU.S.grappleswiththelasting

Peter Hotez and the public health issue of online harassment

AdobeFather’sDayweekendwasanythingbutcalmonTwitter,whicheruptedasvaccineexpertPeterHotezwaschallenge

Telehealth startups turn to complex chronic diseases

MollyFergusonforSTATIfherneurologistmovedtoChina,LaurenStilessaysshe’dfollowhimthere.“There’ssofewdo